Novel Therapeutics for Immunological Diseases
Developing safer, more durable treatments to improve the lives of patients
More

ALTB-168 Neihulizumab
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with ALTB-268.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
ALTB-268
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase 1 Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Preclinical Renal Transplantation Non-Human Primate preclinical studies ongoing.